🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢📢 Everything you wanted to know about #TargetedTherapy in #PancreaticCancer. Check out Educational session "Now and Next in Pancreatic Cancer" at #ASCO2021. Accompanying article ascopubs.org/doi/10.1200/ED… Anirban Maitra Dr. Allyson Ocean ASCO ASCO Publications MD Anderson Cancer Center bhawna sirohi

First interim results of KEYNOTE-811 suggest #Pembrolizumab may become part of the standard of care for patients w HER2-positive advanced #gastriccancer and #GEJcancer ➡️ fal.cn/3fSqA Nataliya Uboha Yelena Y. Janjigian MD #ASCO21 #ASCODailyNews #gicsm

While there is much more work to be done, the field of thoracic oncology has seen tremendous advances in the past decade. I am sure that in 10 years, the list would be filled with more molecular targets and more effective/novel therapies. #LCSM

ascopubs.org/doi/pdf/10.120… Excellent article by ⁦Suresh S. Ramalingam, MD, FASCO⁩ on immunotherapy for non small cell lung cancer ⁦ASCO Publications⁩ ⁦OncoAlert⁩

#WorldGI2021 @Natera results for St II-III #coloncancer ctDNA: 95% are (+) pre surgery. if (+) at 4w post surgery -> 94% sensitivity and HR 17.1 for recurrence! Better than TNM. if (-) post surgery-> 99% 6mo RFS.

In case you missed it! Updated #NCCNGuidelines for GEC distinguishes 1L anti-PD1 w a tiered approach based on PDL1 CPS score. OncoAlert CPS 0: not listed for anti-PD1 tx for any histology! (also EMA approved pembro 5/24/21 #KN590 for AC&SCC only CPS>10) RU checking PDL1?👇

Hem/Onc Board Review Great reminder to not get excited by newer therapies and stick to #OldIsGold for now at least! See #algorithms in excellent review by Mayo Clinic Hematology-Oncology Fellowship star fellows Dr. Tella and Dr. Kommalapatti with Mitesh Borad, M.D. Dr Amit Mahipal Mayo Clinic Comprehensive Cancer Center The Lancet Oncology bit.ly/3zdB4Kh

Now available: our new standards & recommendations for #telehealth in #oncology 💻 fal.cn/3h5e5

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer ja.ma/3B0iG8V via JAMA Oncology part of JAMA Network

In recognition of #PancreaticCancerAwarenessMonth in November, here are five things everyone should know about #PancreaticCancer: cancerblog.mayoclinic.org/2021/11/22/5-t… #pancsm PanCAN

In 2021, 5 new drugs/indications were approved for GI malignancies by FDA Oncology: - Ivosidenib - Nivo in adj settings - Nivo + chemo - Pembro + chemo - TDxd Here is a summary! #GastricCancer #MedEd OncoAlert ASCO #GIOncology #CRCSM #MedTwitter #OncTwitter #Oncology

For those who can’t keep track of all the KEYNOTE and CHECKMATE trials for GEJ Tumors. Need to add the recent KEYNOTE 811 to this chart. #GI22 ASCO

Finally published. ⁦ 👇🏼👇🏼 @mkatzmd⁩ ⁦Flavio G Rocha, MD, FACS, FSSO⁩ ⁦@kharofaJ⁩ ⁦Davendra Sohal⁩ ⁦SWOG Cancer Research Network⁩ Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable PDAC: Dutch Randomized PREOPANC Trial ascopubs.org/doi/pdf/10.120…

What else would you add to this slide?🤔 I prepared this for a talk today to Oncology Nursing Society Clinical Care Options. Find it useful to remind myself of the key 🔑 biomarkers to test for each GI cancer for which there’s at least an approval/guideline recommendation. #MedEd OncoAlert

#ASCO22- Plenary-worthy DYNAMIC RTC results show ctDNA- informed management of Stage2 #coloncancer reduces adjuvant chemotherapy use (28vs15%) without adversely affecting RFS, non-inferiority met. Congrats Dr.Tie! ⁦NEJM⁩ ⁦Pashtoon Kasi MD, MS⁩ ⁦Earle A. Chiles Research Institute⁩ ⁦

#WCGIC2022:Results of the TRIPLETE study highlight the importance of performing randomised clinical trials to avoid unnecessary toxicity. Evidence-based care is the best care we can provide. 👇Learn more in the #VisualAbstract Angela Lamarca

Impressive data from NICHE-2! Of 107 pts with dMMR colon cancer, 95% achieved a MPR and 67% achieved pCR after 1 dose of ipi and 2 of nivo. No relapses seen in the first 13 months of follow up. Can’t wait to attend the full presentation by Myriam Chalabi. oncologypro.esmo.org/meeting-resour…

⭐️⭐️Two major announcements for (Her-2 negative) Gastric/GEJ cancer ⭐️⭐️⭐️ TWO trials have met their end points (PFS, OS) for front line treatment of metastatic gastric/GEJ cancer. 1) Zolbetuximab + Chemo for CLDN18.2 ➕ 2) Pembro+Chemo Cant wait for results!

Eliminate ABIMs MOC requirement - Sign the Petition! chng.it/WrKPbddt via Change.org

I am glad these results are out. Guidelines jumped the gun on incorporating sidedness for mCRC treatment. Insurance companies started denying therapy even when molecular data pointed otherwise.. Patients suffered. #gi24